Wave Life Sciences
- Country
- πΈπ¬Singapore
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 268
- Market Cap
- $704.7M
- Introduction
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03508947
- Locations
- πΊπΈ
Rare Disease Research, LLC., Atlanta, Georgia, United States
π§πͺUZ Gent, Gent, Belgium
π§πͺUniversitaire Ziekenhuizen Leuven, Leuven, Belgium
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT03225846
- Locations
- πΊπΈ
University of California San Diego, La Jolla, California, United States
πΊπΈUniversity of California Davis Medical Center, Sacramento, California, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT03225833
- Locations
- π¦πΊ
Westmead Hospital, Sidney, New South Wales, Australia
π¦πΊRoyal Brisbane & Women's Hospital, Herston, Queensland, Australia
π¦πΊRoyal Melbourne Hospital, Carlton, Victoria, Australia